SERPINE1 and ovarian carcinoma: In vitro invasion assays revealed that IMD-4482 significantly impaired the invasion of PAI-1-positive ovarian cancer cells in a dose-dependent manner (3 mmol/L: SKOV3ip1, 37%; HeyA8, 52%; Figure 3C).